The year 2017 was marked by steady progress in Intec’s development program of AP-CDLD for the treatment of Parkinson’s disease (PD). The drug is a co-formulation of widely used carbidopa and levodopa using the company’s proprietary accordion pill (AP) technology. The program is in Phase III with more than 300 (of 420) patients enrolled to date with full enrolment expected in H218.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs